Cargando…
Evaluation of Novel Enhancer Compounds in Gentamicin-Mediated Readthrough of Nonsense Mutations in Rett Syndrome
Rett syndrome (RTT), a severe X-linked neurodevelopmental disorder, is primarily caused by mutations in the methyl CpG binding protein 2 gene (MECP2). Over 35% RTT patients carry nonsense mutation in MECP2, making it a suitable candidate disease for nonsense suppression therapy. In our previous stud...
Autores principales: | Wong, Keit Men, Wegener, Eike, Baradaran-Heravi, Alireza, Huppke, Brenda, Gärtner, Jutta, Huppke, Peter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380790/ https://www.ncbi.nlm.nih.gov/pubmed/37511424 http://dx.doi.org/10.3390/ijms241411665 |
Ejemplares similares
-
Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model
por: Brendel, Cornelia, et al.
Publicado: (2010) -
Erratum to: Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model
por: Brendel, Cornelia, et al.
Publicado: (2013) -
Characterization of the MeCP2(R168X) Knockin Mouse Model for Rett Syndrome
por: Wegener, Eike, et al.
Publicado: (2014) -
Nonaminoglycoside compounds induce readthrough of nonsense mutations
por: Du, Liutao, et al.
Publicado: (2009) -
Compound heterozygous variants in PGAP1 causing severe psychomotor retardation, brain atrophy, recurrent apneas and delayed myelination: a case report and literature review
por: Kettwig, Matthias, et al.
Publicado: (2016)